8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Bristol-Myers Squibb Company Ce(CELG-RI)Earnings, Financials & Key Ratios
CELG-RI•NYSE
0.0× P/E·Price updated Jun 19, 2026
AboutBristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.Show more
- Revenue$48.19B-0.2%
- EBITDA$19.24B-0.1%
- Net Income$7.05B+178.8%
- EPS (Diluted)3.46+178.5%
- Gross Margin65.9%+16.0%
- EBITDA Margin39.92%+0.1%
- Operating Margin31.37%+56.9%
- Net Margin14.64%+179.0%
- ROE40.43%+203.6%
CELG-RI Key Insights
Bristol-Myers Squibb Company Ce (CELG-RI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 26.7% free cash flow margin
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗High debt to equity ratio of 2.6x
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CELG-RI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CELG-RI Price & Volume
Bristol-Myers Squibb Company Ce (CELG-RI) stock price & volume — 10-year historical chart
Loading chart...
CELG-RI Growth Metrics
Bristol-Myers Squibb Company Ce (CELG-RI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.27%
5 Years2.54%
3 Years1.45%
TTM1.78%
Profit CAGR
10 Years15.82%
5 Years-
3 Years3.69%
TTM34.25%
EPS CAGR
10 Years13.56%
5 Years-
3 Years5.46%
TTM33.57%
Return on Capital
10 Years14.31%
5 Years13.48%
3 Years15.68%
Last Year22.32%
CELG-RI Recent Earnings
Bristol-Myers Squibb Company Ce (CELG-RI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/9 qtrs (50%)●Beat Revenue 5/9 qtrs (100%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.58+11.3%
$1.42
Rev
$11.5B+5.1%
$10.9B
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.26+2.4%
$1.23
Rev
$12.5B+1.8%
$12.3B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.08-28.9%
$1.52
Rev
$12.2B+3.1%
$11.9B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
—
$1.09
Rev
$12.3B+7.2%
$11.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.58vs $1.42+11.3% | $11.5Bvs $10.9B+5.1% |
| Q1 2026 | Feb 5, 2026 | $1.26vs $1.23+2.4% | $12.5Bvs $12.3B+1.8% |
| Q4 2025 | Oct 30, 2025 | $1.08vs $1.52-28.9% | $12.2Bvs $11.9B+3.1% |
| Q3 2025 | Jul 31, 2025 | —vs $1.09 | $12.3Bvs $11.4B+7.2% |
Based on last 9 quarters of dataView full earnings history →
CELG-RI Peer Comparison
Bristol-Myers Squibb Company Ce (CELG-RI) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 |
Compare CELG-RI vs Peers
Bristol-Myers Squibb Company Ce (CELG-RI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELG-RI Income Statement
Bristol-Myers Squibb Company Ce (CELG-RI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 20.78B | 22.56B | 26.14B | 42.52B | 46.38B | 46.16B | 45.01B | 48.3B | 48.19B | 48.48B |
Revenue Growth % | 6.94% | 8.59% | 15.89% | 62.62% | 9.1% | -0.49% | -2.5% | 7.32% | -0.22% | 1.78% |
Cost of Goods Sold | 6.07B | 6.55B | 8.08B | 11.77B | 9.94B | 10.14B | 10.69B | 20.87B | 16.44B | 16B |
COGS % of Revenue | 29.2% | 29.02% | 30.9% | 27.69% | 21.43% | 21.96% | 23.76% | 43.2% | 34.1% | - |
Gross Profit | 14.71B▲ 0% | 16.01B▲ 8.9% | 18.07B▲ 12.8% | 30.75B▲ 70.2% | 36.45B▲ 18.5% | 36.02B▼ 1.2% | 34.31B▼ 4.7% | 27.43B▼ 20.1% | 31.76B▲ 15.8% | 32.48B▲ 0% |
Gross Margin % | 70.8% | 70.98% | 69.1% | 72.31% | 78.57% | 78.04% | 76.24% | 56.79% | 65.9% | 67% |
Gross Profit Growth % | 1.58% | 8.86% | 12.82% | 70.17% | 18.54% | -1.16% | -4.74% | -20.05% | 15.77% | - |
Operating Expenses | 11.26B | 10.9B | 12.15B | 28.57B | 27.91B | 26.92B | 26.12B | 17.77B | 16.64B | 17.11B |
OpEx % of Revenue | 54.2% | 48.3% | 46.49% | 67.19% | 60.17% | 58.32% | 58.03% | 36.8% | 34.53% | - |
Selling, General & Admin | 4.85B | 4.55B | 4.87B | 7.66B | 7.69B | 7.81B | 7.77B | 7.87B | 7.15B | 7.18B |
SG&A % of Revenue | 23.34% | 20.17% | 18.63% | 18.02% | 16.58% | 16.93% | 17.27% | 16.28% | 14.83% | - |
Research & Development | 6.41B | 6.34B | 6.15B | 11.14B | 10.2B | 9.51B | 9.3B | 11.16B | 9.49B | 9.49B |
R&D % of Revenue | 30.86% | 28.12% | 23.52% | 26.21% | 21.98% | 20.6% | 20.66% | 23.1% | 19.7% | - |
Other Operating Expenses | 0 | 0 | 1.14B | 9.76B | 10.02B | 9.6B | 9.05B | -1.25B | 0 | 1000K |
Operating Income | 3.45B▲ 0% | 5.12B▲ 48.3% | 5.91B▲ 15.5% | 2.18B▼ 63.2% | 8.54B▲ 292.1% | 9.1B▲ 6.6% | 8.2B▼ 10.0% | 9.66B▲ 17.9% | 15.12B▲ 56.5% | 15.37B▲ 0% |
Operating Margin % | 16.61% | 22.69% | 22.62% | 5.12% | 18.4% | 19.72% | 18.21% | 20% | 31.37% | 31.7% |
Operating Income Growth % | -23.99% | 48.35% | 15.53% | -63.18% | 292.15% | 6.64% | -9.98% | 17.85% | 56.52% | - |
EBITDA | 4.32B | 5.82B | 7.66B | 12.56B | 19.22B | 19.38B | 17.95B | 19.26B | 19.24B | 18.46B |
EBITDA Margin % | 20.8% | 25.8% | 29.29% | 29.53% | 41.44% | 41.99% | 39.89% | 39.87% | 39.92% | 38.07% |
EBITDA Growth % | -16.32% | 34.68% | 31.58% | 63.95% | 53.09% | 0.82% | -7.35% | 7.26% | -0.1% | 1.88% |
D&A (Non-Cash Add-back) | 872M | 703M | 1.75B | 10.38B | 10.69B | 10.28B | 9.76B | 9.6B | 4.12B | 3.09B |
EBIT | 5.33B | 6.15B | 5.63B | -5.45B | 9.43B | 8.95B | 9.61B | -6.43B | 15.12B | 15.37B |
Net Interest Income | -196M | -183M | -656M | -1.42B | -1.33B | -1.23B | -1.17B | -1.95B | -1.3B | -1.26B |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 586M | 552M |
Interest Expense | 196M | 183M | 656M | 1.42B | 1.33B | 1.23B | 1.17B | 1.95B | 1.89B | 1.81B |
Other Income/Expense | -108M | -426M | -938M | -9.05B | -439M | -1.39B | 245M | -18.04B | -5.79B | -5.77B |
Pretax Income | 5.13B▲ 0% | 6.01B▲ 17.1% | 4.97B▼ 17.2% | -6.87B▼ 238.1% | 8.1B▲ 217.9% | 7.71B▼ 4.8% | 8.44B▲ 9.4% | -8.38B▼ 199.3% | 9.33B▲ 211.3% | 9.6B▲ 0% |
Pretax Margin % | 24.7% | 26.64% | 19.03% | -16.16% | 17.46% | 16.71% | 18.75% | -17.35% | 19.36% | 19.79% |
Income Tax | 4.16B | 1.03B | 1.51B | 2.12B | 1.08B | 1.37B | 400M | 554M | 2.27B | 2.32B |
Effective Tax Rate % | 81% | 17.15% | 30.45% | -30.91% | 13.39% | 17.74% | 4.74% | -6.61% | 24.36% | 24.22% |
Net Income | 1.01B▲ 0% | 4.95B▲ 391.8% | 3.44B▼ 30.6% | -9.02B▼ 362.1% | 6.99B▲ 177.6% | 6.33B▼ 9.5% | 8.03B▲ 26.8% | -8.95B▼ 211.5% | 7.05B▲ 178.8% | 7.28B▲ 0% |
Net Margin % | 4.85% | 21.95% | 13.15% | -21.2% | 15.08% | 13.71% | 17.83% | -18.53% | 14.64% | 15.01% |
Net Income Growth % | -77.41% | 391.76% | -30.55% | -362.14% | 177.58% | -9.54% | 26.84% | -211.5% | 178.83% | 34.25% |
Net Income (Continuing) | 975M | 4.95B | 3.46B | -8.99B | 7.01B | 6.34B | 8.04B | -8.93B | 7.06B | 7.27B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 106M | 96M | 100M | 60M | 60M | 57M | 55M | 53M | 33M | 34M |
EPS (Diluted) | 0.61▲ 0% | 3.03▲ 396.7% | 2.01▼ 33.7% | -3.98▼ 298.0% | 3.12▲ 178.4% | 2.95▼ 5.4% | 3.86▲ 30.8% | -4.41▼ 214.2% | 3.46▲ 178.5% | 3.55▲ 0% |
EPS Growth % | -76.98% | 396.72% | -33.66% | -298.01% | 178.39% | -5.45% | 30.85% | -214.25% | 178.46% | 33.57% |
EPS (Basic) | 0.61 | 3.03 | 2.02 | -3.98 | 3.15 | 2.97 | 3.88 | -4.41 | 3.47 | - |
Diluted Shares Outstanding | 1.65B | 1.64B | 1.71B | 2.26B | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B | 2.05B |
Basic Shares Outstanding | 1.65B | 1.63B | 1.71B | 2.26B | 2.22B | 2.13B | 2.07B | 2.03B | 2.03B | 2.04B |
Dividend Payout Ratio | 255.91% | 52.77% | 77.9% | - | 62.85% | 73.24% | 59.12% | - | 71.52% | - |
CELG-RI Balance Sheet
Bristol-Myers Squibb Company Ce (CELG-RI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.85B | 8.88B | 29.35B | 30.19B | 33.26B | 27.27B | 31.77B | 29.78B | 29.39B | 27.21B |
Cash & Short-Term Investments | 6.81B | 8.88B | 12.35B | 16.54B | 17.22B | 9.25B | 12.28B | 10.86B | 10.67B | 10.49B |
Cash Only | 5.42B | 6.91B | 12.35B | 14.63B | 13.98B | 9.12B | 11.46B | 10.35B | 10.21B | 9.57B |
Short-Term Investments | 1.39B | 1.97B | 0 | 1.9B | 3.24B | 130M | 816M | 513M | 464M | 912M |
Accounts Receivable | 6.3B | 5.75B | 7.68B | 10.3B | 12.52B | 13.94B | 15.26B | 11.13B | 14.53B | 9.37B |
Days Sales Outstanding | 110.68 | 92.98 | 107.29 | 88.42 | 98.49 | 110.21 | 123.79 | 84.12 | 110.01 | 100.9 |
Inventory | 1.17B | 1.2B | 4.29B | 2.07B | 2.1B | 2.34B | 2.66B | 2.56B | 2.69B | 2.76B |
Days Inventory Outstanding | 70.16 | 66.62 | 193.98 | 64.3 | 76.93 | 84.22 | 90.87 | 44.72 | 59.74 | 47.07 |
Other Current Assets | 0 | 1.12B | 5.03B | 1.28B | 1.43B | 1.74B | 1.56B | 1.94B | 1.5B | 4.6B |
Total Non-Current Assets | 18.7B | 1.77B | 100.59B | 88.29B | 76.05B | 69.55B | 63.39B | 62.82B | 60.65B | 59.27B |
Property, Plant & Equipment | 5B | 5.03B | 6.25B | 6.75B | 6.97B | 7.47B | 8.04B | 8.36B | 9.13B | 7.66B |
Fixed Asset Turnover | 4.15x | 4.49x | 4.18x | 6.30x | 6.66x | 6.18x | 5.60x | 5.78x | 5.28x | 7.68x |
Goodwill | 6.86B | 6.54B | 22.49B | 20.55B | 20.5B | 21.15B | 21.17B | 21.72B | 21.75B | 21.74B |
Intangible Assets | 1.21B | 1.09B | 63.97B | 53.24B | 42.77B | 36.35B | 27.07B | 23.31B | 19.1B | 18.24B |
Long-Term Investments | 2.48B | 1.77B | 767M | 4.85B | 2.71B | 2.19B | 2.5B | 2.51B | 2.51B | 7.12B |
Other Non-Current Assets | 1.53B | -14.03B | 6.6B | 1.75B | 1.66B | 1.04B | 1.84B | 2.69B | 2.78B | 6.45B |
Total Assets | 33.55B▲ 0% | 10.66B▼ 68.2% | 129.94B▲ 1119.1% | 118.48B▼ 8.8% | 109.31B▼ 7.7% | 96.82B▼ 11.4% | 95.16B▼ 1.7% | 92.6B▼ 2.7% | 90.04B▼ 2.8% | 86.48B▲ 0% |
Asset Turnover | 0.62x | 2.12x | 0.20x | 0.36x | 0.42x | 0.48x | 0.47x | 0.52x | 0.54x | 0.53x |
Asset Growth % | -0.46% | -68.23% | 1119.1% | -8.82% | -7.74% | -11.43% | -1.72% | -2.69% | -2.77% | -5.74% |
Total Current Liabilities | 9.56B | 1.7B | 18.3B | 19.08B | 21.87B | 21.89B | 22.26B | 23.77B | 23.42B | 19.16B |
Accounts Payable | 2.25B | 1.89B | 2.44B | 2.71B | 2.95B | 3.04B | 3.26B | 3.6B | 3.58B | 4.23B |
Days Payables Outstanding | 135.27 | 105.48 | 110.48 | 84.11 | 108.29 | 109.46 | 111.24 | 63 | 79.39 | 99.96 |
Short-Term Debt | 987M | 1.7B | 3.35B | 2.5B | 4.95B | 4.26B | 3.12B | 2.05B | 2.46B | 2.31B |
Deferred Revenue (Current) | 83M | 172M | 4.49B | 0 | 3.69B | 1.34B | 4.22B | 0 | 0 | 0 |
Other Current Liabilities | 5.11B | 5.61B | -79M | 11.8B | 174M | 2.87B | 456M | 15.17B | 14.84B | 12.62B |
Current Ratio | 1.55x | 5.22x | 1.60x | 1.58x | 1.52x | 1.25x | 1.43x | 1.25x | 1.26x | 1.42x |
Quick Ratio | 1.43x | 4.51x | 1.37x | 1.47x | 1.43x | 1.14x | 1.31x | 1.15x | 1.14x | 1.28x |
Cash Conversion Cycle | 45.58 | 54.12 | 190.79 | 68.61 | 67.13 | 84.97 | 103.41 | 65.85 | 90.36 | 48.01 |
Total Non-Current Liabilities | 12.14B | 5.65B | 59.94B | 61.52B | 51.44B | 43.81B | 43.41B | 52.44B | 48.12B | 47.22B |
Long-Term Debt | 6.97B | 5.65B | 43.39B | 48.34B | 39.6B | 35.06B | 36.65B | 47.6B | 44.68B | 42.15B |
Capital Lease Obligations | 0 | 0 | 672M | 833M | 874M | 1.26B | 1.53B | 1.37B | 1.83B | 5.22B |
Deferred Tax Liabilities | 0 | -4.56B | 6.45B | 5.41B | 4.5B | 2.17B | 338M | 369M | 222M | 905M |
Other Non-Current Liabilities | 4.71B | 4.09B | 9.01B | 6.59B | 6.13B | 5.05B | 4.59B | 2.87B | 1.22B | 4.85B |
Total Liabilities | 21.7B | 7.35B | 78.25B | 80.6B | 73.31B | 65.7B | 65.67B | 76.22B | 71.53B | 66.37B |
Total Debt | 7.96B | 7.35B | 47.54B | 51.67B | 45.6B | 40.72B | 41.46B | 51.2B | 48.97B | 44.46B |
Net Debt | 2.54B | 438M | 35.19B | 37.04B | 31.62B | 31.59B | 30B | 40.85B | 38.76B | 34.89B |
Debt / Equity | 0.67x | 0.52x | 0.92x | 1.36x | 1.27x | 1.31x | 1.41x | 3.12x | 2.65x | 2.21x |
Debt / EBITDA | 1.84x | 1.26x | 6.21x | 4.12x | 2.37x | 2.10x | 2.31x | 2.66x | 2.55x | 2.41x |
Net Debt / EBITDA | 0.59x | 0.08x | 4.59x | 2.95x | 1.64x | 1.63x | 1.67x | 2.12x | 2.01x | 1.89x |
Interest Coverage | 27.18x | 33.61x | 8.58x | -3.84x | 7.07x | 7.26x | 8.24x | -3.30x | 7.99x | 8.50x |
Total Equity | 11.85B▲ 0% | 14.13B▲ 19.2% | 51.7B▲ 266.0% | 37.88B▼ 26.7% | 36.01B▼ 5.0% | 31.12B▼ 13.6% | 29.48B▼ 5.2% | 16.39B▼ 44.4% | 18.51B▲ 12.9% | 20.1B▲ 0% |
Equity Growth % | -27.53% | 19.25% | 265.95% | -26.72% | -4.95% | -13.58% | -5.25% | -44.42% | 12.92% | 38.74% |
Book Value per Share | 7.17 | 8.63 | 30.20 | 16.78 | 16.04 | 14.50 | 14.19 | 8.08 | 9.08 | 9.82 |
Total Shareholders' Equity | 11.74B | 14.03B | 51.6B | 37.82B | 35.95B | 31.06B | 29.43B | 16.34B | 18.47B | 20.07B |
Common Stock | 221M | 221M | 292M | 292M | 292M | 292M | 292M | 292M | 292M | 292M |
Retained Earnings | 31.16B | 34.06B | 34.47B | 21.28B | 23.82B | 25.5B | 28.77B | 14.91B | 16.9B | 18.29B |
Treasury Stock | -19.25B | -19.57B | -25.36B | -26.24B | -31.26B | -38.62B | -43.77B | -43.66B | -43.58B | 0 |
Accumulated OCI | -2.29B | -2.76B | -1.52B | -1.84B | -1.27B | -1.28B | -1.55B | -1.24B | -1.52B | -1.37B |
Minority Interest | 106M | 96M | 100M | 60M | 60M | 57M | 55M | 53M | 33M | 34M |
CELG-RI Cash Flow Statement
Bristol-Myers Squibb Company Ce (CELG-RI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 5.28B | 5.94B | 8.07B | 14.05B | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B | 13.31B |
Operating CF Margin % | 25.39% | 26.33% | 30.85% | 33.05% | 34.94% | 28.31% | 30.8% | 31.45% | 29.37% | - |
Operating CF Growth % | 85.09% | 12.61% | 35.81% | 74.19% | 15.34% | -19.38% | 6.08% | 9.6% | -6.81% | -17.75% |
Net Income | 975M | 4.95B | 3.46B | -8.99B | 7.01B | 6.34B | 8.04B | -8.93B | 7.05B | 7.28B |
Depreciation & Amortization | 789M | 637M | 1.75B | 10.38B | 10.69B | 10.28B | 9.76B | 9.6B | 4.12B | 3.65B |
Stock-Based Compensation | 199M | 221M | 441M | 779M | 583M | 457M | 518M | 507M | 0 | 422M |
Deferred Taxes | 1.01B | 86M | -924M | 983M | -1.39B | -2.74B | -3.29B | -2.09B | -965M | -1.03B |
Other Non-Cash Items | 714M | -127M | 279M | 9.92B | 570M | 955M | 744M | 15.29B | 4.4B | 1.57B |
Working Capital Changes | 1.59B | 176M | 3.06B | 983M | -1.25B | -2.23B | -1.91B | 810M | -455M | 1.42B |
Change in Receivables | -431M | -267M | 1.66B | -2.95B | -2.12B | -663M | -995M | 264M | -295M | 1.38B |
Change in Inventory | -29M | -216M | 463M | 2.67B | 13M | -69M | -751M | -486M | -184M | -1M |
Change in Payables | 320M | -59M | 229M | 188M | 245M | 109M | 198M | 184M | -2M | 492M |
Cash from Investing | -66M | -874M | -9.77B | -10.86B | -538M | -1.06B | -2.29B | -21.35B | -4.13B | -3.76B |
Capital Expenditures | -1.05B | -951M | -836M | -753M | -973M | -1.12B | -1.21B | -1.25B | -1.31B | -1.4B |
CapEx % of Revenue | 5.08% | 4.22% | 3.2% | 1.77% | 2.1% | 2.42% | 2.69% | 2.58% | 2.72% | 2.88% |
Acquisitions | 14M | 3M | -8.78B | -12.21B | -862M | -2.98B | -260M | -21.82B | -2.87B | -4.17B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1.72B | 1.32B | 0 | 0 | 0 | 0 | 0 | 1.1B | 0 | 1.37B |
Cash from Financing | -4.08B | -3.54B | 7.62B | -1.15B | -16.22B | -16.96B | -9.42B | 5.13B | -10.35B | -10.91B |
Debt Issued (Net) | 991M | -548M | 17.65B | 3.93B | -6.18B | -5.31B | 456M | 10.1B | -5.17B | -5.54B |
Equity Issued (Net) | -2.47B | -320M | -7.3B | -1.55B | -6.29B | -8B | -5.16B | 0 | 0 | 0 |
Dividends Paid | -2.58B | -2.61B | -2.68B | -4.08B | -4.4B | -4.63B | -4.74B | -4.86B | -5.04B | -5.07B |
Share Repurchases | -2.47B | -320M | -7.3B | -1.55B | -6.29B | -8B | -5.16B | 0 | 0 | 0 |
Other Financing | -22M | -54M | -53M | 542M | 641M | 984M | 27M | -106M | -128M | -302M |
Net Change in Cash | 1.18B▲ 0% | 1.49B▲ 25.8% | 5.91B▲ 296.6% | 2.15B▼ 63.6% | -657M▼ 130.5% | -4.99B▼ 659.7% | 2.19B▲ 144.0% | -1.17B▼ 153.4% | -137M▲ 88.3% | -1.3B▲ 0% |
Free Cash Flow | 4.22B▲ 0% | 4.99B▲ 18.2% | 7.23B▲ 44.9% | 13.3B▲ 83.9% | 15.23B▲ 14.5% | 11.95B▼ 21.6% | 12.65B▲ 5.9% | 13.94B▲ 10.2% | 12.85B▼ 7.9% | 11.91B▲ 0% |
FCF Margin % | 20.31% | 22.11% | 27.66% | 31.28% | 32.84% | 25.88% | 28.11% | 28.87% | 26.65% | 24.56% |
FCF Growth % | 158.1% | 18.22% | 44.94% | 83.92% | 14.55% | -21.57% | 5.88% | 10.2% | -7.87% | -9% |
FCF per Share | 2.55 | 3.05 | 4.22 | 5.89 | 6.79 | 5.57 | 6.09 | 6.88 | 6.30 | 5.82 |
FCF Conversion (FCF/Net Income) | 5.24x | 1.20x | 2.35x | -1.56x | 2.32x | 2.07x | 1.73x | -1.70x | 2.01x | 1.64x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CELG-RI Key Ratios
Bristol-Myers Squibb Company Ce (CELG-RI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.14% | 38.13% | 10.45% | -20.13% | 18.93% | 18.85% | 26.48% | -39.01% | 40.43% | 38.96% |
Return on Invested Capital (ROIC) | 15.58% | 26.52% | 8.74% | 2.02% | 8.98% | 10.48% | 10.06% | 12.41% | 19.8% | 20.77% |
Gross Margin | 70.8% | 70.98% | 69.1% | 72.31% | 78.57% | 78.04% | 76.24% | 56.79% | 65.9% | 67% |
Net Margin | 4.85% | 21.95% | 13.15% | -21.2% | 15.08% | 13.71% | 17.83% | -18.53% | 14.64% | 15.01% |
Debt / Equity | 0.67x | 0.52x | 0.92x | 1.36x | 1.27x | 1.31x | 1.41x | 3.12x | 2.65x | 2.21x |
Interest Coverage | 27.18x | 33.61x | 8.58x | -3.84x | 7.07x | 7.26x | 8.24x | -3.30x | 7.99x | 8.50x |
FCF Conversion | 5.24x | 1.20x | 2.35x | -1.56x | 2.32x | 2.07x | 1.73x | -1.70x | 2.01x | 1.64x |
Revenue Growth | 6.94% | 8.59% | 15.89% | 62.62% | 9.1% | -0.49% | -2.5% | 7.32% | -0.22% | 1.78% |
Related:CELG-RI Dividend History·CELG-RI Revenue History·CELG-RI Price History·CELG-RI P/E History·CELG-RI Financial Ratios·CELG-RI Institutional Holders
CELG-RI SEC Filings & Documents
Bristol-Myers Squibb Company Ce (CELG-RI) SEC filings — annual & quarterly reports (10-K, 10-Q)
CELG-RI Frequently Asked Questions
Bristol-Myers Squibb Company Ce (CELG-RI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bristol-Myers Squibb Company Ce (CELG-RI) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.
Bristol-Myers Squibb Company Ce (CELG-RI) saw revenue decline by 0.2% over the past year.
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).
Dividend & Returns
Yes, Bristol-Myers Squibb Company Ce (CELG-RI) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Bristol-Myers Squibb Company Ce (CELG-RI) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.
Bristol-Myers Squibb Company Ce (CELG-RI) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.